Surgical Oncology
Volume 19, Issue 1 , Pages 38-45 , March 2010

A meta-analysis of chemotherapy regimen Fluorouracil/Leucovorin/Oxaliplatin Compared with Fluorouracil/Leucovorin in treating advanced colorectal cancer

  • Mian Ling Chen

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 136 0001 0096; fax: +86 020 8104 5937.
    • ,
  • Chi Hua Fang

      Affiliations

    • Department of General Surgery, Zhu Jiang Hospital, Southern Medical University, Guang Zhou, Guang Dong 510282, PR China
    • ,
  • Liu Sen Liang

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • ,
  • Li Hua Dai

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China
    • ,
  • Xiao Kang Wang

      Affiliations

    • Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China

,Accepted 24 February 2009.

References 

  1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal caner. Journal of Clinical Oncology. 2004;22(1):23–30
  2. Figer A, Perez-Staub N, Carola E, Tourniqand C, Lledo G, Flesch M, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer. 2007;110(12):2666–2671
  3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology. 2000;18(16):2938–2947
  4. Wasserberg N, Kaufman HS. Palliation of colorectal cancer. Surgical Oncology. 2007;16:299–310
  5. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato(trans-1-1, 2-diaminocyclohexane) platinum (II): new experimental data. Biomedicine & Phamacotherapy. 1989;43:251–260
  6. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic C, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs. 1997;8:876–885
  7. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drup approval summaries: oxaliplatin. The Oncologist. 2004;9:8–12
  8. Hospers GAP, Schaapveld M, Nortier JW, Wils J, van Bochove A, de Jong RS, et al. Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Annals of Oncology. 2006;17:443–449
  9. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Journal of Clinical Oncology. 2004;22(23):4753–4761
  10. Rothernberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Journal of Clinical Oncology. 2003;21(11):2059–2069
  11. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faqqiuolo R, Focan C, et al. Phases III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 2000;18:136–147

PII: S0960-7404(09)00037-1

doi: 10.1016/j.suronc.2009.02.015

Surgical Oncology
Volume 19, Issue 1 , Pages 38-45 , March 2010

Article Tools